
New Biomarker Study of Rapid-Acting Treatment for Acute Depression
Apimostinel is in development for the treatment of acute depressive disorders and depression with suicidality.
Anantha Shekhar, MD, PhD, discusses Gate Neuroscience's phase 1 study of rapid-acting antidepressant, apimostinel.
You can read more about apimostinel in "
Dr Shekhar is senior vice chancellor for the health sciences and John and Gertrude Petersen Dean of the School of Medicine at the University of Pittsburgh. He is also a professor of psychiatry and a professor of clinical and translational science, as well as Chief Scientific Officer of Gate Neuroscience.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.